CL2018002848A1 - Formulaciones liquidas de fosfoplatino - Google Patents

Formulaciones liquidas de fosfoplatino

Info

Publication number
CL2018002848A1
CL2018002848A1 CL2018002848A CL2018002848A CL2018002848A1 CL 2018002848 A1 CL2018002848 A1 CL 2018002848A1 CL 2018002848 A CL2018002848 A CL 2018002848A CL 2018002848 A CL2018002848 A CL 2018002848A CL 2018002848 A1 CL2018002848 A1 CL 2018002848A1
Authority
CL
Chile
Prior art keywords
phosphoplatin
formulations
liquid
pirodach
cancer
Prior art date
Application number
CL2018002848A
Other languages
English (en)
Inventor
Wayne D Luke
Tyler Ames
Original Assignee
Phosplatin Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phosplatin Therapeutics Llc filed Critical Phosplatin Therapeutics Llc
Publication of CL2018002848A1 publication Critical patent/CL2018002848A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS DE COMPUESTOS DE FOSFAPLATINO, EN PARTICULAR FORMULACIONES LÍQUIDAS ESTABLES AMORTIGUADAS DE PIRODACH-2 LISTAS PARA USAR EN EL TRATAMIENTO DE DIVERSOS TIPOS DE CÁNCER, Y MÉTODOS DE PREPARACIÓN.
CL2018002848A 2016-04-06 2018-10-05 Formulaciones liquidas de fosfoplatino CL2018002848A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662319047P 2016-04-06 2016-04-06

Publications (1)

Publication Number Publication Date
CL2018002848A1 true CL2018002848A1 (es) 2018-12-21

Family

ID=60000715

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002848A CL2018002848A1 (es) 2016-04-06 2018-10-05 Formulaciones liquidas de fosfoplatino

Country Status (18)

Country Link
US (1) US11154529B2 (es)
EP (1) EP3439650A4 (es)
JP (2) JP2019510831A (es)
KR (1) KR102419247B1 (es)
CN (1) CN109310663B (es)
AU (1) AU2017246883B2 (es)
BR (1) BR112018070603A2 (es)
CA (1) CA3020166A1 (es)
CL (1) CL2018002848A1 (es)
CO (1) CO2018011420A2 (es)
EA (1) EA039525B1 (es)
IL (1) IL262066A (es)
MX (1) MX2018012223A (es)
PH (1) PH12018502139A1 (es)
SG (1) SG11201808717QA (es)
TW (1) TWI798175B (es)
WO (1) WO2017176880A1 (es)
ZA (1) ZA201806530B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7023968B2 (ja) * 2017-01-06 2022-02-22 フォスプラティン・セラピューティクス・インコーポレーテッド 骨がんまたは血液がんの治療のための治療薬としてのホスファプラチン化合物
JP2023547835A (ja) * 2020-10-20 2023-11-14 プロモントリー・セラピューティクス・インコーポレイテッド 高解糖性腫瘍細胞を選択的に標的化する治療剤としてのホスファプラチン化合物及びその方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4463274B2 (ja) * 2003-06-27 2010-05-19 明 小谷 ビスホスホネート錯体
AP3480A (en) * 2010-06-04 2015-12-31 Univ Ohio Phosphaplatins and their use for treatment of cancers
WO2012096722A1 (en) 2011-01-12 2012-07-19 Ohio University Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof
MX357865B (es) * 2011-10-05 2018-07-25 N Bose Rathindra Procedimientos eficientes para preparación a gran escala de agentes antitumorales de fosfaplatinos.
CN104010508B (zh) * 2011-10-05 2017-03-15 理辛德拉·N·博斯 用于大规模制备磷铂类抗肿瘤剂的高效方法
PL3202769T3 (pl) 2012-05-24 2020-03-31 Phosplatin Therapeutics Llc Sposoby oczyszczania związków fosfaplatyny

Also Published As

Publication number Publication date
MX2018012223A (es) 2019-05-30
JP2023014110A (ja) 2023-01-26
EA201892157A1 (ru) 2019-04-30
PH12018502139A1 (en) 2019-09-23
AU2017246883B2 (en) 2023-02-09
CN109310663B (zh) 2022-05-31
CO2018011420A2 (es) 2019-02-08
IL262066A (en) 2018-11-29
US11154529B2 (en) 2021-10-26
US20200323810A1 (en) 2020-10-15
CA3020166A1 (en) 2017-10-12
EA039525B1 (ru) 2022-02-07
CN109310663A (zh) 2019-02-05
BR112018070603A2 (pt) 2019-02-05
AU2017246883A1 (en) 2018-11-08
TW201737920A (zh) 2017-11-01
JP2019510831A (ja) 2019-04-18
TWI798175B (zh) 2023-04-11
KR20180133889A (ko) 2018-12-17
KR102419247B1 (ko) 2022-07-11
EP3439650A1 (en) 2019-02-13
ZA201806530B (en) 2019-07-31
SG11201808717QA (en) 2018-11-29
WO2017176880A1 (en) 2017-10-12
EP3439650A4 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
CL2015000942A1 (es) Compuestos de benceno sustituido.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
CL2015002897A1 (es) Inhibidores de bace1
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas